Relief Therapeutics’ Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment
Relief Therapeutics Holding SA’s (OTC:RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of…
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review
The FDA has accepted for review Acer Therapeutics Inc (NASDAQ:ACER) and its partner, Relief Therapeutics Holding SA’s (OTC:RLFTF) marketing application for ACER-001 (sodium…
Acer Therapeutics and Relief Therapeutics Announced FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders With PDUFA Target Action Date of June 5, 2022
Acer Therapeutics Inc. (Nasdaq: ACER) ("Acer") and its collaboration partner, RELIEF THERAPEUTICS Holding SA (OTC: RLFTF) ("Relief"), today announced that the U.S.
Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock is up more than 26% during the premarket trading on Friday.